Suggested remit: To appraise the clinical and cost effectiveness of nivolumab in combination with ipilimumab within its marketing authorisation for untreated metastatic non-small-cell lung cancer.
Following on from information provided to NICE by the company in February 2020, the appraisal of Nivolumab in combination with ipilimumab for untreated metastatic non-small-cell lung cancer [ID1675] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1675
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 November 2022 | Discontinued. Following on from information provided to NICE by the company in February 2020, the appraisal of Nivolumab in combination with ipilimumab for untreated metastatic non-small-cell lung cancer [ID1675] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 04 February 2020 | Note added to the project documents |
| 04 February 2020 | Suspended. Company no longer pursuing a license in the UK |
| 18 December 2019 | In progress. Referred December 5 2017 |
For further information on our processes and methods, please see our CHTE processes and methods manual